Autor

Hallett TB

julio 13, 2021
Vidas salvadas con la vacunación para 10 patógenos en 112 países en un mundo anterior a COVID-19
Summary Background Vaccination is one of the most effective public health interventions. We investigate the impact of vaccination activities for Haemophilus influenzae type b, hepatitis B, human papillomavirus, Japanese encephalitis, measles, Neisseria meningitidis serogroup A, rotavirus, rubella, Streptococcus pneumoniae, and yellow fever over the years 2000-2030 across 112 countries. Methods Twenty-one mathematical models estimated disease burden using standardised demographic and […]

Leer más
30 de enero de 2021
Estimación del impacto en la salud de la vacunación contra diez patógenos en 98 países de ingresos bajos y medianos entre 2000 y 2030: un estudio de modelos
Summary Background The past two decades have seen expansion of childhood vaccination programmes in low-income and middle-income countries (LMICs). We quantify the health impact of these programmes by estimating the deaths and disability-adjusted life-years (DALYs) averted by vaccination against ten pathogens in 98 LMICs between 2000 and 2030. Methods 16 independent research groups provided model-based […]

Leer más
agosto 10, 2020
Modelado de la infección por el virus de la hepatitis B e impacto de la vacuna con dosis de nacimiento oportuna: comparación de dos modelos de simulación
Summary Hepatitis B is a global epidemic that requires carefully orchestrated vaccination initiatives in geographical regions of medium to high endemicity to reach the World Health Organization’s elimination targets by 2030. This study compares two widely-used deterministic hepatitis B models—the Imperial HBV model and the CDA Foundation’s PRoGReSs—based on their predicted outcomes in four countries. […]

Leer más
30 de enero de 2018
El caso de inversión para la hepatitis B y C en Sudáfrica: adaptación e innovación en el análisis de políticas para la ampliación del programa de enfermedades
Summary Even though WHO has approved global goals for hepatitis elimination, most countries have yet to establish programs for hepatitis B and C, which account for 320 million infections and over a million deaths annually. One reason for this slow response is the paucity of robust, compelling analyses showing that national HBV/HCV programs could have […]

Leer más